David Frankel, MD
Psychiatry · Philadelphia, PANPI 1811052574
Payments from drug & device makers
Across 428 payments — averaging $19.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Neurocrine Biosciences, Inc.$1K
- Johnson & Johnson$774
- Alkermes, Inc.$585
- Vanda Pharmaceuticals Inc.$554
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$476
- plus $4K from 20 others
What the payments were for
- Speaking & faculty fees$4005%
- Food & beverage$7,77194%
- Education$1041%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 76 | $1,281 |
| Neurocrine Biosciences, Inc. | 48 | $1,025 |
| Johnson & Johnson | 26 | $774 |
| Alkermes, Inc. | 33 | $585 |
| Vanda Pharmaceuticals Inc. | 30 | $554 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 26 | $476 |
| Teva Pharmaceuticals USA, Inc. | 26 | $455 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $435 |
| Otsuka America Pharmaceutical, Inc. | 19 | $396 |
| Corium, LLC | 20 | $360 |
| Supernus Pharmaceuticals, Inc. | 25 | $357 |
| Sunovion Pharmaceuticals Inc. | 20 | $310 |
| Lundbeck LLC | 9 | $209 |
| E.r. Squibb & Sons, L.L.C. | 8 | $201 |
| Axsome Therapeutics, Inc. | 6 | $151 |
| Tris Pharma Inc | 7 | $143 |
| Boston Scientific | 1 | $126 |
| Indivior Inc. | 5 | $100 |
| Avanir Pharmaceuticals, Inc. | 6 | $93 |
| Noven Therapeutics, LLC | 5 | $73 |
| Idorsia Pharmaceuticals US Inc | 3 | $54 |
| Almatica Pharma LLC | 2 | $45 |
| Luye Pharma (USA) Ltd. | 1 | $22 |
| Sage Therapeutics, LLC | 1 | $20 |
| Noven Pharmaceuticals, Inc. | 1 | $17 |
| Neos Therapeutics, LP | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,275 in reported general payments places this provider in the 90th percentile of 1,838 psychiatry providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 42 | $416,547 |
| VraylarCariprazine Hcl | 183 | $297,577 |
| Invega SustennaPaliperidone Palmitate | 41 | $112,167 |
| RexultiBrexpiprazole | 33 | $49,789 |
| Risperdal ConstaRisperidone Microspheres | 39 | $45,195 |
| TrintellixVortioxetine Hydrobromide | 58 | $36,298 |
| CaplytaLumateperone Tosylate | 21 | $35,002 |
| LybalviOlanzapine/Samidorphan Malate | 13 | $33,010 |
| Aripiprazole | 199 | $11,194 |
| Paliperidone ErPaliperidone | 36 | $8,660 |
| Quetiapine Fumarate | 522 | $6,732 |
| Lisdexamfetamine Dimesylate | 31 | $6,379 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 205 | $6,216 |
| Mirtazapine | 376 | $5,928 |
| Clozapine | 100 | $5,598 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,025 | $416,54742 claims |
| AbbVieVraylar | $1,281 | $297,577183 claims |
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $774 | $157,36280 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $396 | $49,78933 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $435 | $36,29858 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $476 | $35,00221 claims |
| Alkermes, Inc.Lybalvi | $585 | $33,01013 claims |
| Almatica Pharma LLCSertraline Hcl | $45 | $1,468185 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,838 psychiatry providers in Pennsylvania.
Other psychiatry in Philadelphia
- Steven ArnoldPhiladelphia$4.1M
- Michael ThasePhiladelphia$2.2M
- Daniel WeintraubPhiladelphia$647K
- Yvette ShelinePhiladelphia$442K
- Kyle KampmanPhiladelphia$355K
- Christian KohlerPhiladelphia$172K
- Freddy AliPhiladelphia$107K
- Stanley CaroffPhiladelphia$105K
- Richard JaffePhiladelphia$101K
- Ramesh EluriPhiladelphia$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.